A rival's setback is this small cap's gain, right?
The titanium dioxide manufacturer announced progress on its proposed acquisition of Cristal.
Most investors have probably never heard of this small-cap laboratory equipment supplier, but it reached an important inflection point in 2018.
The company secured a deal paving the way to commercialize a generic version of the former best-selling drug in the world.
An important phase 3 clinical trial enrolled its last patient at the beginning of the year, which means top-line results could be right around the corner.
The gene-editing pioneer announced a new regulatory designation for its lead drug candidate.
The company reported preliminary full-year 2018 results and set expectations for a solid year of growth in 2019.
The company's lead drug candidate got thrown into a whirlwind of uncertainty.
Two well-managed renewable energy businesses are not getting much love from Wall Street right now, but the high-yield stocks are great long-term buys.
The pharma company reported positive results from an important phase 3 trial.
The paper company recovered after an awful December and then proved Wall Street wrong with full-year 2018 operating results.
One of America's largest electric utilities has committed to generating all of its electricity from zero-carbon sources by 2050. Will peers follow?
Wall Street soured on this water utility after it announced a massive acquisition in a new industry, but that could change when full-year 2018 earnings are reported.
The group rebounded after a terrible end to 2018, but each has big plans for the year ahead.
Also, never buy a penny stock.
The life sciences hardware provider reported full-year 2018 earnings results.
The company announced fiscal first-quarter 2019 financial results and provided an update for the year ahead.
The company announced disappointing early results for a muscular dystrophy gene therapy.
The biodiesel leader rebounded after a sour end to 2018, although investors have plenty to look forward to in the years ahead.
The pharma company is taking the FDA to court over the regulator's insistence on animal testing.